Regulation of cytochrome P450 3A4 by small vault RNAb derived from the non-coding vault RNA1 of multidrug resistance-linked vault particle

Meng,Chunjie; Wei,Zhiyun; Zhang,Yiting; Yan,Liang; He,Hang; Zhang,Lirong; Xing,Qinghe

doi:10.3892/mmr.2016.5228

Regulation of cytochrome P450 3A4 by small vault RNAb derived from the non-coding vault RNA1 of multidrug resistance-linked vault particle

Authors:
- Chunjie Meng
- Zhiyun Wei
- Yiting Zhang
- Liang Yan
- Hang He
- Lirong Zhang
- Qinghe Xing
View Affiliations

Affiliations: Children's Hospital and Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, P.R. China, Department of Pharmacology, School of Medicine, Zhengzhou University, Zhengzhou, Henan 450006, P.R. China
Published online on: May 9, 2016 https://doi.org/10.3892/mmr.2016.5228
Pages: 387-393

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cytochrome P450 3A4 (CYP3A4) is the most abundant cytochrome P450 enzyme in human liver and intestine, contributing to the metabolism of >60% of all pharmaceuticals. The expression levels of hepatic CYP3A4 show great inter‑individual variation. However, the detailed regulatory mechanism of CYP3A4 expression has remained largely elusive. It has been reported that the non‑coding RNA small vault (sv)RNAb targets the 3' untranslated region (3'UTR) of CYP3A4 in MCF7 cells. However, to date, the role of svRNAb has not been examined in human liver tissue and hepatic cell lines such as HepG2, which was the aim of the present study. Polymerase chain reaction analysis indicated that the expression of CYP3A4 was significantly different within a study cohort (n=19). In addition, a significant negative correlation was observed between svRNAb and CYP3A4 expression in human liver tissue samples. Furthermore, a luciferase assay on HepG2 cells verified that svRNAb directly targets CYP3A4 and regulates the expression of CYP3A4 by interacting with the validated binding sites of the CYP3A4 3'UTR. The results provided insight into the variation of the expression of CYP3A4 among individuals and provided a novel method for the adjustment of personalized drug treatment. Furthermore, the present study provided a mechanism of the regulatory role of svRNAb in multidrug‑resistant cells.

View Figures

View References

1	Westlind A, Malmebo S, Johansson I, Otter C, Andersson TB, Ingelman-Sundberg M and Oscarson M: Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43. Biochem Biophys Res Commun. 281:1349–1355. 2001. View Article : Google Scholar : PubMed/NCBI
2	Sevrioukova IF and Poulos TL: Understanding the mechanism of cytochrome P450 3A4: recent advances and remaining problems. Dalton transactions. 42:3116–3126. 2013. View Article : Google Scholar :
3	de Wildt SN, Kearns GL, Leeder JS and van den Anker JN: Cytochrome P450 3A: Ontogeny and drug disposition. Clin Pharmacokinet. 37:485–505. 1999. View Article : Google Scholar
4	Lamba JK, Lin YS, Schuetz EG and Thummel KE: Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 54:1271–1294. 2002. View Article : Google Scholar : PubMed/NCBI
5	Urquhart BL, Tirona RG and Kim RB: Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: Implications for interindividual variability in response to drugs. J Clin Pharmacol. 47:566–578. 2007. View Article : Google Scholar : PubMed/NCBI
6	Keshava C, McCanlies EC and Weston A: CYP3A4 polymorphisms-potential risk factors for breast and prostate cancer: A HuGE review. Am J Epidemiol. 160:825–841. 2004. View Article : Google Scholar : PubMed/NCBI
7	Wojnowski L and Kamdem LK: Clinical implications of CYP3A polymorphisms. Expert Opin Drug Metab Toxicol. 2:171–182. 2006. View Article : Google Scholar : PubMed/NCBI
8	Perera MA: The missing linkage: What pharmacogenetic associations are left to find in CYP3A? Expert Opin Drug Metab Toxicol. 6:17–28. 2010. View Article : Google Scholar
9	Klein K and Zanger UM: Pharmacogenomics of Cytochrome P450 3A4: Recent progress toward the ῾Missing Heritability᾿ problem. Front Genet. 4:122013. View Article : Google Scholar
10	Kitazono M, Sumizawa T, Takebayashi Y, Chen ZS, Furukawa T, Nagayama S, Tani A, Takao S, Aikou T and Akiyama S: Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells. J Natl Cancer Inst. 91:1647–1653. 1999. View Article : Google Scholar : PubMed/NCBI
11	Willson TM and Kliewer SA: PXR, CAR and drug metabolism. Nat Rev Drug Discov. 1:259–266. 2002. View Article : Google Scholar : PubMed/NCBI
12	Timsit YE and Negishi M: CAR and PXR: The xenobiotic-sensing receptors. Steroids. 72:231–246. 2007. View Article : Google Scholar : PubMed/NCBI
13	Klein K, Thomas M, Winter S, Nussler AK, Niemi M, Schwab M and Zanger UM: PPARA: A novel genetic determinant of CYP3A4 in vitro and in vivo. Clin Pharmacol Ther. 91:1044–1052. 2012. View Article : Google Scholar : PubMed/NCBI
14	Oda Y, Nakajima M, Tsuneyama K, Takamiya M, Aoki Y, Fukami T and Yokoi T: Retinoid X receptor α in human liver is regulated by miR-34a. Biochem Pharmacol. 90:179–187. 2014. View Article : Google Scholar : PubMed/NCBI
15	Yang J, Hao C, Yang D, Shi D, Song X, Luan X, Hu G and Yan B: Pregnane X receptor is required for interleukin-6-mediated down-regulation of cytochrome P450 3A4 in human hepatocytes. Toxicol Lett. 197:219–226. 2010. View Article : Google Scholar : PubMed/NCBI
16	Watanabe K, Sakurai K, Tsuchiya Y, Yamazoe Y and Yoshinari K: Dual roles of nuclear receptor liver X receptor α (LXRα) in the CYP3A4 expression in human hepatocytes as a positive and negative regulator. Biochem Pharmacol. 86:428–436. 2013. View Article : Google Scholar : PubMed/NCBI
17	Goodwin B, Hodgson E, D'Costa DJ, Robertson GR and Liddle C: Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor. Mol Pharmacol. 62:359–365. 2002. View Article : Google Scholar : PubMed/NCBI
18	Wang K, Chen S, Xie W and Wan YJ: Retinoids induce cytochrome P450 3A4 through RXR/VDR-mediated pathway. Biochem Pharmacol. 75:2204–2213. 2008. View Article : Google Scholar : PubMed/NCBI
19	Thirumaran RK, Lamba JK, Kim RB, Urquhart BL, Gregor JC, Chande N, Fan Y, Qi A, Cheng C, Thummel KE, et al: Intestinal CYP3A4 and midazolam disposition in vivo associate with VDR polymorphisms and show seasonal variation. Biochem Pharmacol. 84:104–112. 2012. View Article : Google Scholar : PubMed/NCBI
20	Jones SA, Moore LB, Shenk JL, Wisely GB, Hamilton GA, McKee DD, Tomkinson NC, LeCluyse EL, Lambert MH, Willson TM, et al: The pregnane X receptor: A promiscuous xenobiotic receptor that has diverged during evolution. Mol Endocrinol. 14:27–39. 2000. View Article : Google Scholar : PubMed/NCBI
21	Aitken AE and Morgan ET: Gene-specific effects of inflammatory cytokines on cytochrome p450 2c, 2b6 and 3a4 mrna levels in human hepatocytes. Drug Metab Dispos. 35:1687–1693. 2007. View Article : Google Scholar : PubMed/NCBI
22	Dickmann LJ, Patel SK, Wienkers LC and Slatter JG: Effects of Interleukin 1β (IL-1β) and IL-1β/interleukin 6 (IL-6) combinations on drug metabolizing enzymes in human hepatocyte culture. Curr Drug Metab. 13:930–937. 2012. View Article : Google Scholar : PubMed/NCBI
23	Wolbold R, Klein K, Burk O, Nüssler AK, Neuhaus P, Eichelbaum M, Schwab M and Zanger UM: Sex is a major determinant of CYP3A4 expression in human liver. Hepatology. 38:978–988. 2003. View Article : Google Scholar : PubMed/NCBI
24	Vilalta A, Kickhoefer VA, Rome LH and Johnson DL: The rat vault RNA gene contains a unique RNA polymerase III promoter composed of both external and internal elements that function synergistically. J Biol Chem. 269:29752–29759. 1994.PubMed/NCBI
25	Kickhoefer VA, Rajavel KS, Scheffer GL, Dalton WS, Scheper RJ and Rome LH: Vaults are up-regulated in multidrug-resistant cancer cell lines. J Biol Chem. 273:8971–8974. 1998. View Article : Google Scholar : PubMed/NCBI
26	van Zon A, Mossink MH, Schoester M, Scheffer GL, Scheper RJ, Sonneveld P and Wiemer EA: Multiple human vault RNAs: expression and association with the vault complex. J Biol Chem. 276:37715–37721. 2001. View Article : Google Scholar : PubMed/NCBI
27	Kitazono M, Okumura H, Ikeda R, Sumizawa T, Furukawa T, Nagayama S, Seto K, Aikou T and Akiyama S: Reversal of LRP-associated drug resistance in colon carcinoma SW-620 cells. Int J Cancer. 91:126–131. 2001. View Article : Google Scholar : PubMed/NCBI
28	Patel J and Mitra AK: Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs. Pharmacogenomics. 2:401–415. 2001. View Article : Google Scholar : PubMed/NCBI
29	Siva AC, Raval-Fernandes S, Stephen AG, LaFemina MJ, Scheper RJ, Kickhoefer VA and Rome LH: Up-regulation of vaults may be necessary but not sufficient for multidrug resistance. Int J Cancer. 92:195–202. 2001. View Article : Google Scholar : PubMed/NCBI
30	Persson H, Kvist A, Vallon-Christersson J, Medstrand P, Borg A and Rovira C: The non-coding RNA of the multidrug resistance-linked vault particle encodes multiple regulatory small RNAs. Nat Cell Biol. 11:1268–1271. 2009. View Article : Google Scholar : PubMed/NCBI
31	Michaelis L and Menten ML: Die kinetik der invertinwirkung. Biochem Z. 49:333–369. 1913.
32	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar